The original review had presented entropy as a way to quantify uncertainty in medical reasoning, describing it as offering a concise summary of uncertainty that nonetheless lacks a built-in mechanism for action. That admission, the Singapore authors contend, is precisely where the trouble begins. In clinical practice, uncertainty is not merely a quantity to be measured; it is a condition to be navigated, weighed against risks, benefits, and patient values, and ultimately resolved into a decision: treat, test, observe, or reassure. A framework that summarizes uncertainty without specifying how to act on it, they argue, risks creating what they call an illusion of precision, presenting clinicians with a single descriptive number that feels rigorous but resists translation into a concrete clinical act.

The technical heart of the critique lies in a comparison between entropy and Bayesian inference, the dominant framework for reasoning under uncertainty in medicine and statistics. Bayesian models produce state-specific probabilities: the probability, for instance, that a patient with chest pain is having a myocardial infarction versus a benign cause. These actionable probabilities can then be compared against established decision thresholds, most famously formalized by Pauker and Kassirer in the New England Journal of Medicine in 1980. The threshold approach defines a testing threshold and a treatment threshold; if the probability of disease falls below the former, the clinician forgoes testing, and if it rises above the latter, treatment proceeds without further diagnostic workup. This architecture converts probability directly into action, providing a rational bridge between belief and behavior.

Entropy, by contrast, collapses an entire probability distribution into a single scalar. In information theory, the Shannon entropy of a diagnostic hypothesis set is maximal when all possibilities are equally likely and minimal when one diagnosis dominates. A high-entropy differential diagnosis tells the clinician that the situation is genuinely uncertain, but it does not say which diagnosis is most probable, what test would most efficiently reduce the uncertainty, or whether further investigation is even warranted given the stakes. Two patients could carry identical entropy values while demanding radically different management: one with a high-mortality condition hovering near a treatment threshold, the other with a trivial condition with little actionable consequence. The letter’s authors argue that this loss of state-specific information is not a minor technicality but an ontological mismatch between the descriptive reach of entropy and the prescriptive demands of clinical judgment.

The critique also engages with the literature on value of information, a family of methods for prioritizing research and testing by quantifying how much a new piece of information would be worth in terms of improved outcomes. Value of information analysis, as codified by Jackson and colleagues in Epidemiologic Methods in 2021, builds explicitly on decision-theoretic foundations, linking the acquisition of information to expected gains in health. Bayesian probability combined with threshold logic naturally accommodates these calculations: knowing a probability and the payoff matrix of actions allows one to compute the expected value of perfect or sample information. Entropy alone, stripped of state-specific probabilities and payoff structures, cannot perform this function. A clinician told that a case has an entropy of 1.7 bits has learned little about what to do next, whereas a clinician told that the probability of disease is 45 percent against a testing threshold of 30 percent knows immediately that more information is worth acquiring.

What makes the letter particularly provocative is its pivot from decision theory to pedagogy. The authors acknowledge that the original review rightly locates entropy’s true promise in standardization and scalability, especially for artificial intelligence systems trained on vast clinical datasets. In that context, entropy can serve as a useful computational statistic, a way for machine learning systems to flag cases of high diagnostic ambiguity, route them to specialists, or measure model confidence. But the authors warn that the vision of an “entropy-based medicine” must be weighed against its potential educational consequences. Medicine has long oscillated between the aspiration to quantify everything and the recognition that its core practice remains an interpretive, human activity. If trainees learn that good clinical reasoning means minimizing a calculated uncertainty value, the letter suggests, they may lose sight of a more important competency: the cultivated ability to tolerate uncertainty and still act responsibly.

That argument draws on a growing body of medical education scholarship, most prominently the 2016 New England Journal of Medicine perspective by Simpkin and Schwartzstein titled “Tolerating uncertainty — the next medical revolution?” That piece argued that discomfort with uncertainty drives a range of pathology in modern medicine, from excessive diagnostic testing and defensive medicine to communication failures and burnout. Uncertainty tolerance, far from being a soft skill, is framed as a professional capacity intimately linked to clinical judgment, effective patient communication, and patient safety. The Singapore authors build directly on this framing: an “entropy-minimization” mindset, they caution, could distract trainees from the deeper goal of becoming comfortable living with ambiguity. In a busy clinical environment, the temptation to chase a single number that promises clarity is strong, and a pedagogy built around minimizing entropy could reinforce precisely the reflexive, test-driven behavior that educators have spent years trying to moderate.

The debate also carries implications for how artificial intelligence tools will be explained and governed in medicine. As machine learning systems become embedded in triage, imaging interpretation, and predictive analytics, measures of model uncertainty such as entropy will increasingly be surfaced to clinicians, perhaps as confidence scores or risk flags. The letter’s warning suggests that how these numbers are taught, contextualized, and displayed will matter enormously. A confidence metric presented without a decision threshold or a treatment implication invites either blind deference or reflexive dismissal. Used well, however, uncertainty quantification can prompt exactly the right kind of reflection: a pause before acting on a low-confidence prediction, a request for a second opinion, or a conversation with the patient about the limits of what is known. The difference lies not in the mathematics but in the professional culture that surrounds it.

None of this amounts to a rejection of information theory in medicine. The letter is explicit in crediting the original review with a valuable service: introducing a complex concept to a general medical audience and sparking a necessary dialogue on the nature of clinical uncertainty. Its authors position their critique as a call for deeper conversation rather than a dismissal, insisting that before the profession embraces new quantitative tools, it must clarify their proper place in a practice that remains both a science and an art. The historical parallel is instructive. Bayesian reasoning took decades to move from statistical journals into bedside teaching, and only became genuinely useful to clinicians once it was paired with threshold frameworks, likelihood ratios, and pretest probability estimation. Entropy, if it follows a similar path, will need its own translation layer: ways of connecting a global uncertainty measure to the specific probabilities, stakes, and values that drive individual decisions.

For now, the Singapore letter stands as a compact but pointed intervention in one of the most consequential conversations in contemporary medicine: how a profession built on judgment should metabolize the quantitative machinery of the information age. Its message resonates well beyond internal medicine, touching any field wrestling with the promise of AI-assisted uncertainty quantification, from radiology to public health modeling. The core claim is deceptively simple. Measuring uncertainty is not the same as managing it, and a number that summarizes doubt without pointing toward action may, in the hands of an overburdened clinician or a trainee still forming professional habits, do more to obscure good judgment than to support it. As hospitals and developers race to embed uncertainty metrics in clinical workflows, this letter insists that the decisive questions are not computational but philosophical and pedagogical: what do we want clinicians to learn when we teach them to measure what they do not know?

Subject of Research: The limitations of entropy as a quantitative measure of clinical uncertainty in medical decision-making, judgment, and education.

Article Title: Beyond Entropy: Decision Thresholds, Judgment, and Pedagogy

Article References: Sadasiv, M. S., & Chow, M. (2026). Beyond Entropy: Decision Thresholds, Judgment, and Pedagogy. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10746-3

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10746-3

Keywords: entropy, clinical decision-making, uncertainty, Bayesian inference, decision thresholds, medical education, clinical judgment, artificial intelligence, decision theory, value of information, diagnostic uncertainty, internal medicine

The research, led by Xinyi Liu, Xiao Han, and Jianjun Chen with colleagues including Guanghua Zhou, Guohong Li, and Xianqun Fan, tackles a problem that has dogged health policymakers well beyond China. Digital transformation has become a strategic priority for health systems from the United States to Germany to Australia, propelled by electronic health records, telemedicine, artificial intelligence, and big data analytics. But knowing whether a hospital is genuinely “digitally mature” — as opposed to simply owning a lot of software — has remained stubbornly elusive. International yardsticks exist, such as the HIMSS Electronic Medical Record Adoption Model, which grades hospitals along an eight-stage pathway from minimal digital adoption to fully integrated electronic record environments, and the United Kingdom’s NHS Digital Maturity Assessment, which broadens the lens to include infrastructure, interoperability, leadership, and innovation readiness. Yet these frameworks were built for health systems with very different institutional arrangements, regulatory environments, and hospital structures than China’s.

China’s context is distinctive in scale and complexity. The country’s hospitals operate within a rigid hierarchy and referral system, follow national e-governance standards, and number in the tens of thousands of public institutions serving a geographically dispersed population of 1.4 billion. Pressures from an aging population, a rising chronic disease burden, and constrained traditional delivery models have made digitization a national imperative, enshrined in the Healthy China 2030 blueprint and the broader Digital China initiative. Chinese regulators have not been idle: in 2018 the National Health Commission introduced a nine-level evaluation scale for electronic health record adoption, with explicit criteria and deadlines. But according to the researchers, what has been missing is a standardized, context-specific framework capable of measuring digital maturity comprehensively across Chinese tertiary hospitals — and, crucially, of being validated against real-world data rather than self-reported aspirations.

The framework the team constructed rests on three primary dimensions: Digital Readiness, Technology Application, and Data Management Capability. Beneath these sit 11 subdimensions and 65 individual indicators, spanning everything from IT staffing and training to internet-based patient visits and data quality management. The architecture was assembled through a systematic review of English- and Chinese-language literature — searching PubMed, Medline, Web of Science, CNKI, and Wanfang for studies published between 1990 and 2024 — combined with analysis of national policy documents defining the mandate of tertiary public hospitals.

Refining and validating that structure required structured expert consensus. The researchers ran two rounds of Delphi consultations, the classic iterative survey method in which anonymous feedback from a panel converges toward agreement. The first round drew responses from 32 of 40 invited experts, an 80 percent response rate dominated by hospital information management professionals — 81.25 percent of the panel — most holding senior titles and, in nearly six out of ten cases, more than two decades of experience in digital healthcare. The panel spanned eastern, central, and western China, deliberately avoiding a coastal bias. Expert authority was rigorously quantified: each expert’s judgment basis and familiarity were combined into an authority coefficient of 0.853, well above conventional thresholds, and consensus was confirmed using Kendall’s coefficient of concordance, with coefficient-of-variation values below 0.25 indicating acceptable agreement.

The weighting of the 65 indicators is where the study’s methodological ambition becomes most visible. Rather than relying solely on expert opinion, the team fused subjective and objective weighting schemes. Subjective weights came from the analytic hierarchy process, in which experts compare criteria pairwise and the resulting judgment matrices are checked for internal consistency — a consistency ratio below 0.10 was required. Objective weights came from an enhanced version of the CRITIC method, dubbed CRITID, which replaces ordinary Pearson correlation with distance correlation. The distinction matters: distance correlation, built on distance covariance, can detect nonlinear relationships between indicators that linear measures miss entirely. An indicator that varies widely across hospitals and behaves independently of the others earns a larger weight, while redundant, highly correlated indicators are adjusted downward to avoid double counting. Final weights emerged as the normalized product of subjective and objective components, applied bottom-up from indicators to subdimensions to dimensions to an overall maturity score.

When the weights settled, the results were notably balanced. Digital Readiness captured the largest combined share at 34.9 percent, followed almost identically by Technology Application at 34.7 percent, with Data Management Capability close behind at 30.4 percent. That near-even split, the authors argue, reflects something important: digital maturity is not simply a shopping list of technology, but a balanced combination of organizational readiness, technology-enabled service delivery, and data governance. A hospital cannot buy its way to maturity with servers and software alone.

The empirical analysis drew on the 2020 Digitalization Survey conducted by the National Health Commission, administered in 2019 and covering 58.7 percent of China’s tertiary hospitals. After quality control and cleaning, the analytic sample comprised 1,361 tertiary public hospitals from 28 provinces — Qinghai, Guangxi, and Sichuan did not participate. All variables were min-max normalized to a scale from zero to one, with four heavily skewed indicators, including the number of informatization staff and internet-based visits, log-transformed first. To stress-test which indicators actually drove the scores, the team deployed Random Balance Designs Fourier Amplitude Sensitivity Test, a global sensitivity analysis technique that quantifies each indicator’s first-order contribution to output variance. Intriguingly, the sensitivity rankings did not perfectly match the combined weights — a discrepancy the researchers interpret as evidence that expert judgment and empirical influence capture genuinely different aspects of indicator importance.

Hospitals were then sorted into five maturity clusters using k-means clustering, an unsupervised machine learning algorithm that partitions observations by minimizing within-cluster variance around centroids. To probe what separated the digital haves from the have-nots, the researchers ran indicator-specific logistic regressions using Firth’s penalized likelihood — a technique chosen for its robustness against small-sample bias and complete separation problems — adjusting for hospital tier, type, affiliation, and province, with Benjamini-Hochberg false discovery rate correction applied across the many parallel tests.

The verdict on China’s hospital digitization is two-sided. Higher-maturity hospitals scored better across a broad range of indicators, with the sharpest advantages appearing in clinical digital applications and data quality management. In other words, the frontier hospitals are using technology to change how care is actually delivered and how data integrity is maintained — not merely accumulating infrastructure. But one dimension lagged across every maturity group: data sharing and exchange. Even China’s digitally strongest hospitals remain weak at moving information across institutional boundaries, a problem the paper’s introduction traces to thousands of fragmented medical IT systems with limited interoperability — the infamous “information silos” that have hindered Chinese health data exchange for years. The new evidence suggests that a decade of investment has modernized hospitals individually while leaving the connective tissue between them underdeveloped.

The team took robustness seriously. Alternative objective weighting methods — entropy weighting, coefficient-of-variation weighting, and the original linear CRITIC — were compared against CRITID, and the cluster analysis was repeated with Jenks natural breaks, quantile cuts, and finite mixture modelling, with cluster counts ranging from three to seven. The main findings largely survived these perturbations, though the authors candidly acknowledge residual sensitivity to methodological choices, a humility that lends the work credibility. The Delphi component was reported under CREDES guidance and the observational analysis under the STROBE statement, aligning the study with international reporting standards.

The implications stretch well beyond China’s borders. For policymakers in Beijing, the framework offers a diagnostic instrument for monitoring the national digitization push, benchmarking institutions, and targeting investment at the weakest links — data exchange chief among them. For other large, hierarchical, regionally uneven health systems — India, Indonesia, Brazil — the study supplies a transferable template, though the authors caution that application elsewhere would demand local adaptation and empirical validation. Perhaps most consequentially, the researchers flag what the framework cannot yet do: maturity scores have not been validated against actual outcomes. The critical next step, they write, is testing whether digitally mature hospitals truly deliver better quality, safety, efficiency, patient experience, and equity — the question on which the entire global digital health enterprise ultimately rests. With 1,361 hospitals now scored and a validated instrument in hand, that test may finally be within reach.

The warning focuses on England’s NHS 10 Year Plan, which places digital transformation at the centre of future healthcare delivery. The strategy envisages more care delivered in communities, greater use of remote services and data-driven decision-making, and accelerated adoption of advanced technologies. Yet the researchers say that formal clinical safety assessment is not being consistently monitored or enforced. Under requirements associated with the Health and Social Care Act 2012, digital health technologies are expected to undergo structured risk management in accordance with two national standards: DCB0129, which applies to manufacturers and developers, and DCB0160, which applies to organisations deploying technology in clinical settings.

These standards are designed to identify hazards before a system is used with patients and to control risks throughout its operational life. A clinical safety case should normally describe how a technology might cause harm, the likelihood and severity of possible failures, the safeguards in place, and the evidence supporting its safe use. The process also requires organisations to monitor incidents, reassess risks when software or workflows change, and ensure that staff understand how the technology affects clinical decisions. The researchers say that this system is failing in practice. In an earlier freedom of information survey of 239 NHS trusts and integrated care boards, they identified 14,848 digital health technologies in use. Seventy per cent had no documented safety assurance, while only 17% were reported to be fully assured.

The new analysis examined why compliance was so poor. The researchers reanalysed free-text responses from the original survey and assessed previously unpublished information about the capacity of Clinical Safety Officers, or CSOs. These are clinicians tasked with overseeing the management of risks associated with digital systems used in patient care. Among 211 organisations that provided relevant information between February and March 2025, the average reported deployment was approximately one full-time-equivalent CSO per organisation. However, only 163 organisations supplied data about the number of hours actually devoted to digital clinical safety, making the headline figure difficult to interpret.

The difference between formal staffing levels and real working capacity appeared particularly important. NHS trusts reported an average of 1.3 full-time-equivalent staff, whereas integrated care boards reported less than half a post, or approximately 0.4 full-time-equivalent staff. Written responses suggested that these numbers often overstated the resources available because CSO responsibilities were commonly added to existing clinical or managerial jobs. Twenty-two organisations could not quantify the time allocated to implementing the safety standards. In 11 organisations, the CSO role formed part of a senior executive’s duties, including those of an associate medical director, chief clinical information officer or chief nurse. Senior leadership can give safety work influence, the researchers acknowledge, but it can also place responsibility in the hands of people with the least time to conduct detailed assessments or develop specialist expertise.

The responses also exposed weaknesses in the basic infrastructure needed to understand what technologies are being used. Thirty-seven organisations claimed statutory exemptions from the freedom of information request. Cost and the time required to retrieve information were among the most frequently cited reasons, while others reported that their data were inaccessible or that they had no central register of digital tools. The researchers say these explanations may be valid, but they also point to immature governance. Without a reliable inventory, an organisation cannot easily determine which systems influence diagnosis, treatment, prescribing, triage or patient monitoring, let alone whether those systems have been assessed after updates or changes in clinical use.

Some exemptions raised an additional concern. A number of organisations referred to provisions involving the prevention or detection of crime or health and safety. The researchers interpret this as evidence that some organisations may not understand the specific meaning of clinical safety in digital healthcare. Clinical safety is not limited to cybersecurity, physical security or the prevention of deliberate wrongdoing. It includes unintended clinical consequences such as an algorithm generating systematically biased risk scores, an interface encouraging a prescribing error, an alert system producing so many warnings that clinicians ignore them, or a data integration failure causing information to be assigned to the wrong patient. These hazards can emerge even when a system is functioning exactly as its designers intended.

Thematic analysis identified four mutually reinforcing causes of non-compliance: poor understanding of the standards, immature governance and oversight, ineffective assurance processes, and the treatment of the CSO role as an additional task rather than a professionalised safety function. The researchers describe this as a system-level failure rather than a problem attributable to individual clinicians. If staff lack training, organisations lack technology registers, assurance processes are treated as paperwork, and CSOs have little protected time, each weakness amplifies the others. A clinical risk assessment completed once at the point of procurement cannot provide continuous protection when software is updated, datasets change, workflows are redesigned or a tool is deployed in a new population.

The risk could grow as the NHS adopts technologies that are more complex and more deeply embedded in clinical decisions. Artificial intelligence systems may be trained on data that do not represent every patient group and may perform differently after changes in clinical practice. Genomic tools can produce results whose interpretation depends on evolving scientific evidence, while robotic and automated systems can create new interactions between software, hardware and human operators. The planned shift from hospitals into community and primary care could extend these risks to smaller organisations with fewer specialist resources. At the same time, NHS services increasingly involve private, voluntary and other external providers, creating the possibility of accountability gaps when responsibility for a digital system is divided between a developer, commissioner and frontline service.

The researchers propose stronger oversight by the Care Quality Commission, inclusion of DCB0129 and DCB0160 compliance within the patient-safety section of the NHS Oversight Framework, and a formal career pathway for Clinical Safety Officers based on tiered competencies. They also call for mechanisms to share evidence about common deployment hazards, near misses and clinical incidents across the NHS. Their conclusions are limited by the nature of the data: the survey did not provide the depth or opportunity for clarification available through interviews, and it excluded primary care and adult social care, where compliance remains unknown. Even so, the authors argue that the findings reveal a national gap between the NHS’s ambitions for digital innovation and its ability to control clinical risk. They conclude that England needs a new digital safety architecture combining central assessment, local risk management, professionalised safety expertise, regulatory enforcement and integration of digital governance into routine quality standards. Without it, digital transformation could spread unsafe practices at the same scale and speed as the technologies themselves.

Subject of Research: People

Article Title: Unfit for the future? Revisiting the national cross sectional study of digital clinical safety in England’s NHS to identify drivers of low compliance and implications for the 10 Year Health Plan

News Publication Date: 18-Aug-2026

Web References: https://www.gov.uk/government/publications/10-year-health-plan-for-england-fit-for-the-future

References: BMJ Innovations, DOI: 10.1136/6/bmjinnov-2025-001544

Keywords: NHS digital transformation, clinical safety, digital health, Clinical Safety Officers, DCB0129, DCB0160, artificial intelligence, patient safety, healthcare technology, NHS 10 Year Plan

Hosted by the American Heart Association Center for Technology & Innovation, the competition seeks technologies capable of changing how conditions such as high blood pressure, stroke and heart failure are prevented, detected and treated. The program is positioned at the intersection of biomedical research, clinical medicine, data science and health-system operations. By connecting innovators with clinicians, researchers and investors, the Association aims to shorten the distance between a validated prototype and a tool that can be deployed at scale, particularly in communities where limited access, workforce shortages and rising costs continue to delay care.

The need for scalable cardiovascular technologies is underscored by the global burden of disease. Cardiovascular disease remains the leading cause of death worldwide, while health systems are confronting increasing demand for care and persistent shortages of trained personnel. Digital tools can help address those pressures by collecting physiological data outside conventional clinics, identifying risk patterns earlier and supporting clinicians with continuously updated information. Remote monitoring devices, for example, can transmit blood pressure, heart-rate or other patient measurements for analysis between visits. Artificial intelligence systems may then detect trends or abnormalities, although their clinical usefulness depends on the quality of the data, the reliability of the algorithms and the ability of medical teams to act on the results.

Five finalists will present their technologies at Scientific Sessions 2026, the American Heart Association’s flagship international meeting for cardiovascular science and clinical advancement. The event will take place Nov. 6–9 at McCormick Place in Chicago, with the finalists scheduled to deliver live pitches Nov. 7–8. The winner will be announced Nov. 9. Before reaching the stage, applicants will be evaluated on the maturity of their technology, the strength of available clinical or pilot data, the viability of their business model and the potential to improve outcomes across different care settings. Applications remain open through Sept. 18, and the five finalists are scheduled to be announced Oct. 10.

The competition’s emphasis on clinical validation distinguishes it from many startup contests that focus primarily on technical novelty, investment potential or rapid market growth. A health technology intended for cardiovascular care must function within complex clinical workflows, where decisions can have immediate consequences. Developers may need to demonstrate that a system produces accurate measurements, limits false alarms, protects patient information and performs consistently across different populations and devices. They must also show how clinicians will interpret its outputs, how patients will be engaged and how the technology can integrate with electronic health records, telehealth platforms or existing monitoring systems without creating additional burdens for already strained care teams.

Artificial intelligence is likely to be an important component of many emerging health technologies, but the Association’s criteria reflect the growing recognition that algorithmic performance must be evaluated in context. A model that performs well in a controlled dataset may behave differently when exposed to incomplete records, inconsistent measurements or populations that were underrepresented during development. Clinical validation can reveal whether an algorithm improves diagnosis, treatment selection, adherence or patient outcomes rather than merely predicting a condition. For cardiovascular and brain health applications, the most meaningful evidence may include reductions in hospitalizations, faster treatment after stroke, improved blood-pressure control or earlier identification of heart failure deterioration.

“For more than a century, the American Heart Association has been at the intersection of science, research, clinical expertise and innovation to drive improvements in cardiovascular and brain health,” said Nancy Brown, chief executive officer of the American Heart Association. “Through the Health Tech Competition, we continue that work by helping advance evidence-based solutions that address today’s most pressing health challenges and reach people where they live, work and receive care.” The statement reflects the program’s focus on extending care beyond hospitals and specialist offices. Technologies that can support patients at home, in workplaces or in under-resourced communities may be especially important when transportation, cost or geography limits access to traditional services.

The competition is also part of the Health Innovation Pavilion at Scientific Sessions, where scientific findings, clinical tools and commercial technologies will converge before an audience of researchers, physicians, entrepreneurs and investors. That setting gives finalists an opportunity to explain not only what their products do, but also how they were tested and how they could be incorporated into routine care. A successful system might combine wearable sensors, mobile applications, cloud-based analytics and clinician dashboards, but each component must contribute to a clear clinical objective. The value of a connected platform is ultimately measured not by the volume of data it generates, but by whether that information leads to earlier intervention, better decisions or healthier lives.

Previous Association programming has highlighted the growing global appetite for health technologies that can improve heart and brain health. The organization has recognized innovators working to address unmet clinical needs and has used its competition platform to bring young companies into contact with potential partners. By emphasizing evidence-based care, the 2026 program seeks to encourage responsible commercialization rather than the rapid deployment of unproven tools. This approach may also help investors and health systems distinguish between technologies that merely promise disruption and those with measurable clinical, operational or public-health benefits.

Applications and the full terms and conditions for the 2026 Health Tech Competition are available through the American Heart Association’s Center for Technology & Innovation. The finalists’ appearance at Scientific Sessions will offer a public test of how effectively emerging companies can translate technical innovation into practical care. As artificial intelligence, connected devices and remote monitoring become increasingly embedded in medicine, the competition illustrates a broader shift in health technology: the decisive question is no longer whether a system can generate sophisticated data, but whether it can produce trustworthy evidence and deliver meaningful improvements for patients with cardiovascular and brain conditions.

Subject of Research:
Health technology innovation, artificial intelligence, digital health, remote patient monitoring, cardiovascular disease and brain health.

Article Title:
American Heart Association Opens 2026 Health Tech Competition to Accelerate Cardiovascular and Brain Health Innovation

News Publication Date:
August 18, 2026

Web References:
https://ahahealthtech.org/aha-health-tech-competition-2026/
https://ahahealthtech.org/
https://professional.heart.org/en/meetings/scientific-sessions
https://newsroom.heart.org/news/houston-based-medical-technology-company-wins-overall-global-health-tech-competition-at-scientific-sessions-2025
https://newsroom.heart.org/news/finalists-named-in-global-health-technology-competition-to-advance-heart-and-brain-health

References:
Fahim YA, Hasani IW, Kabba S, Ragab WM. “Artificial intelligence in healthcare and medicine: clinical applications, therapeutic advances, and future perspectives.” European Journal of Medical Research. 2025;30(1):848. doi:10.1186/s40001-025-03196-w. PMID: 40988064; PMCID: PMC12455834. https://pubmed.ncbi.nlm.nih.gov/40988064/

Keywords:
American Heart Association, Health Tech Competition 2026, cardiovascular health, brain health, artificial intelligence, digital health, remote patient monitoring, health innovation, clinical validation, stroke, heart failure, hypertension, Scientific Sessions 2026, medical technology, health care technology.

Central venous pressure reflects the pressure in the right atrium and is widely used as an indicator of venous return, cardiac function, and a patient’s response to fluids or vasoactive medications. The conventional reference method requires placement of a central venous catheter, an invasive procedure that can cause bleeding, infection, thrombosis, pneumothorax, or other complications. Although catheterization remains essential for many critically ill patients, it may be unsuitable or technically difficult in people with coagulopathy, infection, distorted anatomy, or limited venous access. Noninvasive alternatives based on physical examination or intermittent ultrasound can provide valuable information, but they are often operator-dependent and do not deliver uninterrupted monitoring. The new system is designed to bridge that gap by combining a neck-worn imaging device with automated interpretation.

At the center of the platform is an ultra-thin, 128-element linear-array ultrasound transducer developed to sit comfortably over the right side of the neck. The probe operates at a center frequency of 8.5 megahertz, a range that provides a balance between fine spatial resolution and sufficient penetration to visualize the internal jugular vein and common carotid artery. These vessels are important because the internal jugular vein connects directly to the right atrium without intervening valves. Changes in its cross-sectional area can therefore reflect variations in right-sided filling pressure and central venous pressure. The adjacent common carotid artery provides an anatomical reference that helps normalize measurements for differences in probe placement, body habitus, and neck geometry.

The patch’s engineering is intended to preserve image quality during prolonged use. Its acoustic structure includes a dual-layer matching system and a customized backing layer, producing an 85% fractional bandwidth and high sensitivity across a broad range of frequencies. A solid hydrogel coupling material maintains acoustic transmission between the probe and skin without requiring a liquid gel that can dry, leak, or become uncomfortable over time. The electronics and transducer are enclosed in silicone, allowing the device to remain attached while patients move or receive routine care. In feasibility testing, the patch was worn for as long as 24 hours while maintaining stable imaging and acceptable skin comfort, raising the possibility of near-continuous vascular surveillance rather than occasional manual examinations.

Continuous ultrasound, however, generates far more information than a clinician can realistically inspect frame by frame. The device produces cine-loop videos of the jugular vein and carotid artery, and each recording may contain thousands of individual images. To automate this process, the researchers created a semi-supervised artificial-intelligence model called the dual-decoder spatiotemporal attention network, or DSTA-Net. Instead of requiring experts to outline the vessels in every frame, the model uses manual annotations for only about 10% of the images. These key frames correspond to points at which the internal jugular vein is near its maximum or minimum dilation, providing highly informative examples of the vessel’s changing geometry.

DSTA-Net learns from the remaining unlabeled frames through a dual-decoder consistency strategy. A shared encoder first converts each ultrasound image into features that represent vessel boundaries, texture, and surrounding anatomy. Two separate decoders then interpret those features in complementary ways: one incorporates temporal attention to track how structures evolve across consecutive frames, while the other uses a lighter pathway to generate an independent segmentation. The model is trained to make the two pathways agree, allowing unlabeled images to serve as additional learning signals. This approach avoids relying on a continuously updated teacher model, a technique that can be vulnerable to unstable or incorrect predictions in noisy ultrasound data. By exploiting the natural temporal continuity of the cine-loop, the network can follow vessel motion while reducing the annotation burden for medical experts.

Testing indicated that the system could segment the internal jugular vein more accurately than several established deep-learning approaches. On an internal dataset, DSTA-Net achieved a Dice similarity coefficient of 83.5%, while its score on an external dataset was 75.8%. The Dice coefficient measures the overlap between the region identified by an algorithm and the region outlined by an expert, with higher values indicating closer agreement. According to the study, the model improved on the strongest fully supervised baselines, including UNet, Swin-UNet, and DeepLabV3+, by approximately 12 percentage points internally and 9 points externally. It also outperformed semi-supervised systems including UniMatch, DWL, and AllSpark. The model’s derived vascular measurements showed Spearman correlation values above 0.88 for most parameters, and Bland–Altman analyses indicated percentage errors well below the commonly cited 30% threshold for clinical agreement.

The segmented images were converted into five vascular indices: the maximum area of the internal jugular vein, its minimum area, the area of the common carotid artery, the ratio between the maximum jugular and carotid areas, and a jugular-vein area ratio reflecting dynamic changes over time. These measurements were combined with age, body mass index, blood pressure, and heart rate in a second artificial-intelligence system known as a dual-modality multilayer perceptron, or DM-MLP. Unlike image-focused architectures such as convolutional ResNets or vision Transformers, the DM-MLP was designed for structured clinical data. Its Attribute-Mixing operation models relationships among different clinical features, while Case-Mixing refines how each feature is represented across patients. The resulting low-rank architecture uses relatively few parameters while retaining the ability to capture nonlinear interactions, and it outperformed ResNet, DenseNet, and Transformer-based alternatives by roughly 4% to 8% in area under the curve.

The clinical evaluation included 349 intensive-care patients, with 272 enrolled at Shanghai Sixth People’s Hospital and 77 at Shanghai Tenth People’s Hospital. The principal target was elevated CVP, defined as a pressure of at least 8 millimeters of mercury. The model reached an AUC of 0.91 on the internal test set and 0.87 on the external test set, indicating strong discrimination between patients above and below the threshold. Additional analyses using thresholds of 7 and 9 millimeters of mercury produced similarly robust results. SHAP-based interpretability analysis suggested that the ultrasound-derived variables, especially maximum internal jugular vein area and the jugular-to-carotid ratio, contributed more strongly to the predictions than conventional variables such as blood pressure and body mass index. The system processed images at approximately 32 frames per second, or about one frame every 30 milliseconds, on a hospital server, enabling near-real-time analysis.

The researchers stress that the technology is not intended to eliminate central venous catheters in every clinical situation. Instead, it could provide a rapid, repeatable assessment when catheterization is contraindicated, delayed, or unnecessary, and could help identify rising venous pressure before a patient undergoes an invasive procedure. The study remains an early demonstration: its cohort is modest for training modern AI systems, it evaluates diagnostic performance rather than whether the technology improves survival or treatment decisions, and some aspects of the semi-supervised model remain difficult to interpret. Future work will expand the number of participating hospitals, test direct prediction of continuous CVP values rather than categories, add interpretability methods such as Grad-CAM, and assess whether AI-guided monitoring changes fluid and vasopressor management. By uniting wearable ultrasound, temporal image analysis, and clinical prediction, the platform brings automated noninvasive hemodynamic monitoring closer to routine use in acute and critical care.

Subject of Research: Wearable ultrasound and artificial intelligence for noninvasive central venous pressure monitoring in intensive-care patients.

Article Title: AI-Enabled Wearable Ultrasound for Noninvasive Central Venous Pressure Monitoring

News Publication Date: August 8, 2026

Web References: DOI: 10.34133/cbsystems.0653

References: Cyborg and Bionic Systems, “AI-Enabled Wearable Ultrasound for Noninvasive Central Venous Pressure Monitoring.”

Image Credits: Liping Zhang, Department of Emergency Medicine, Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine.

Keywords: wearable ultrasound, artificial intelligence, central venous pressure, internal jugular vein, common carotid artery, intensive care, medical imaging, semi-supervised learning, DSTA-Net, DM-MLP, noninvasive monitoring, hemodynamics

Foundation models are designed to learn broad representations from enormous and diverse datasets before being adapted to specific tasks. In biomedical imaging, those data may include magnetic resonance imaging, computed tomography, X-rays, ultrasound, digital pathology slides and ophthalmic images. The same underlying model could theoretically identify tumors, segment organs, estimate disease risk, retrieve similar cases and generate clinical reports. The vision becomes even broader when imaging is combined with pathology, electronic health records and genomic information, creating a composite system intended to analyze a patient across multiple biological scales.

That ambition reflects a major change from traditional medical AI. Earlier systems were generally built for one narrowly defined task, such as detecting pneumonia on chest radiographs or outlining a brain lesion on MRI scans. Foundation models instead attempt to create a reusable backbone that can be transferred across diseases, hospitals and imaging technologies. Technically, they learn statistical patterns in high-dimensional data, often through self-supervised training in which the system predicts missing, transformed or associated information. Afterward, developers fine-tune or prompt the model for particular clinical applications.

But biomedical imaging is not a single, uniform world. Images differ according to scanner manufacturer, acquisition protocol, patient population, disease prevalence and local clinical practice. A model trained primarily on data from large academic hospitals may perform very differently in community clinics, rural settings or countries with limited equipment. This problem, known as domain shift, can occur even when images appear visually similar. Small changes in image quality, contrast, hardware or patient demographics may alter the statistical distribution learned by the model and undermine its predictions.

The authors introduce a framework called real-world evaluation and assessment of foundation models, or REAL-FM, to examine whether these systems are ready for practical use. Rather than focusing only on accuracy scores, REAL-FM considers several dimensions at once, including the quality and representativeness of training data, technical readiness, clinical value, integration into existing workflows and responsible artificial intelligence. The framework is intended to help clinicians interpret claims about new models and to push developers toward evaluations that resemble actual medical practice.

One of the sharpest distinctions in the perspective is between pattern recognition and causal reasoning. Foundation models can become extraordinarily skilled at recognizing visual associations—for example, linking a particular texture or anatomical feature with a diagnosis present in their training data. Yet association is not the same as understanding why a disease occurs, how it will progress or whether a treatment will benefit an individual patient. A model may identify a correlation that is valid in one hospital but reflects a hidden confounder, such as a scanner type, reporting convention or patient-selection pattern, rather than a biological signal.

This limitation becomes especially dangerous when models are moved beyond simplified benchmarks. Many benchmark datasets provide carefully curated images, clear labels and narrowly defined tasks. Clinical care is messier: scans can be incomplete, diagnoses can be uncertain, records may contain contradictory information and several conditions may coexist. The perspective highlights a lack of verified generalization across such conditions, along with a shortage of prospective, outcome-based validation. In a prospective study, an AI system would be evaluated while care is actually being delivered, with researchers measuring whether it improves diagnostic accuracy, treatment decisions, patient outcomes or workflow efficiency.

Data scarcity is another obstacle. The largest foundation models require vast quantities of data, but medical information is difficult to collect, standardize and share. Patient records are fragmented across institutions, imaging data may lack reliable annotations and rare diseases are inherently underrepresented. Privacy regulations and governance requirements further complicate the creation of centralized datasets. As a result, a model may appear broadly capable while remaining poorly tested in the populations and clinical circumstances where errors could have the greatest consequences.

The researchers argue that human oversight therefore remains indispensable. In practical terms, foundation models may be most useful as clinical assistants that prioritize images for review, highlight suspicious regions, summarize longitudinal records or offer a second opinion that specialists can interrogate. Safe deployment will require transparent reporting of uncertainty, monitoring for performance drift, mechanisms for correcting errors and clear accountability when recommendations influence care. The future envisioned by the authors is not a single monolithic medical oracle, but a coordinated ecosystem of specialized AI systems, each evaluated for a defined clinical role and connected to expert-led workflows.

The perspective arrives as the biomedical AI field races toward increasingly general-purpose systems. Its warning is not that foundation models lack value, but that technical scale alone cannot establish clinical reliability. Before these models can be trusted with consequential decisions, they must demonstrate robustness across domains, usefulness in real workflows, safety under unexpected conditions and measurable benefits for patients. The proposed REAL-FM framework offers a way to separate viral demonstrations from durable medical progress—by asking not only what a model can recognize, but where it works, why it works and whether it makes care better.

Subject of Research: Foundation models and their real-world evaluation in biomedical imaging and clinical medicine.

Article Title: Foundation models in biomedical imaging: turning hype into reality

Article References: Muneer, A., Zhang, K., Hamdi, I. et al. Foundation models in biomedical imaging: turning hype into reality. Nature Biomedical Engineering 10, 1557–1575 (2026). https://doi.org/10.1038/s41551-026-01762-z

Image Credits: AI Generated

DOI: 10.1038/s41551-026-01762-z

Keywords: foundation models, biomedical imaging, medical artificial intelligence, clinical AI, multimodal AI, domain shift, causal reasoning, clinical validation, responsible AI, REAL-FM

The rule creates a large administrative challenge for both government agencies and the people they serve. States must determine whether enrollees are meeting the monthly requirement, identify people who qualify for exemptions and provide opportunities to correct incomplete or missing records. A Special Communication published Aug. 7 in JAMA Health Forum argues that carefully designed artificial intelligence systems could help Medicaid agencies perform these tasks while reducing the paperwork burden that has historically caused eligible people to lose coverage.

“Medicaid work requirements introduce administrative complexities into an already very complex program,” said Beth McGinty, professor of population health sciences at Weill Cornell Medicine and co-founding director of the Cornell Health Policy Center. Applying for Medicaid and remaining enrolled already varies widely by state, with confusing forms, changing eligibility rules and multiple documentation requirements. Adding a work or community-engagement standard could create another point at which people lose insurance, even when they are working or legally exempt.

The central concern is not necessarily that enrollees will fail to meet the requirement, but that they will be unable to prove that they meet it. The law directs states to use existing government databases to verify eligibility whenever possible. Yet payroll records, tax information and data from other public programs may be incomplete, delayed or stored in systems that cannot easily communicate with one another. When automated verification fails, the responsibility may shift to individuals, who could be asked to submit pay stubs, exemption forms or other records within strict deadlines.

That problem has precedent. The authors point to earlier research from Arkansas, where some Medicaid recipients lost coverage after facing difficulty documenting compliance with a similar work requirement. Such outcomes are often described as procedural or administrative losses rather than deliberate cancellations: people may qualify under the policy but fail to complete a complex sequence of notices, forms and verification steps. For people with unstable housing, disabilities, limited internet access, irregular employment or demanding caregiving responsibilities, even a technically simple request can become a significant barrier.

Artificial intelligence could help by connecting information that agencies already possess. Yongkang Zhang, Fei Wang, William Schpero and John Ayanian, the authors of the Special Communication with McGinty, propose systems that could link Medicaid enrollment records with payroll and tax data or with participation records from other public programs. In technical terms, such systems would use data integration and record-matching methods to compare information across databases, while algorithms could flag likely matches, identify missing fields and route uncertain cases to human reviewers. If implemented accurately, the approach could verify employment or an exemption without repeatedly asking enrollees for documents.

AI could also be deployed at the front end of the Medicaid system, where applicants and beneficiaries interact with online portals. A digital assistant could explain the work requirement in plain language, answer questions about qualifying activities and identify which documents a person may need. More advanced tools could analyze where users abandon applications, which questions generate repeated errors and which parts of a website prompt people to seek help. That information would allow agencies to redesign confusing forms before those difficulties translate into coverage losses.

Around one-quarter of state Medicaid programs already use AI chatbots for consumer assistance, according to McGinty. Expanding these systems could provide round-the-clock guidance during a policy rollout likely to generate a surge in calls and online inquiries. AI tools could also analyze anonymized call-center transcripts, help-desk messages and website activity to detect emerging problems in near real time. If many people in a state suddenly ask how to document seasonal work, report caregiving or claim a disability-related exemption, administrators could adjust outreach materials and staff training instead of waiting for formal complaints or enrollment data to reveal the problem.

The technology, however, would not eliminate the risks created by the policy. States differ substantially in their information-technology infrastructure, data standards and capacity to develop or supervise AI systems. Poorly designed data matching could incorrectly classify a person as noncompliant, while outdated records could trigger unnecessary requests for documentation. Automated language systems may also misunderstand users with limited English proficiency, disabilities or unusual employment arrangements. Because Medicaid data contains sensitive health, financial and demographic information, agencies would need strong privacy safeguards, access controls, audit trails and procedures for correcting erroneous records.

The researchers emphasize that AI must remain an assistive technology rather than the final decision-maker. Historical data can contain racial, economic and geographic disparities, and algorithms trained on those records may reproduce them at scale. Human staff would need to review ambiguous cases, explain adverse decisions and provide accessible appeals. “This cannot be a ‘hand it over to the bots’ solution,” McGinty said, warning that continuous monitoring and human oversight will be essential. Federal assistance may also be necessary to help lower-capacity states build secure systems. If those safeguards are put in place, AI could do more than speed up administration: it could help governments identify where policy design itself is causing people to fall through the cracks.

Subject of Research: Artificial intelligence applications for implementing Medicaid work requirements and reducing administrative barriers to coverage.

News Publication Date: 7-Aug-2026

Web References: https://jamanetwork.com/journals/jama-health-forum/fullarticle/2852210

References: JAMA Health Forum Special Communication; Weill Cornell Medicine; Cornell Health Policy Center.

Keywords: Medicaid, Medicaid work requirements, artificial intelligence, health policy, health insurance, data analysis, healthcare technology, public health, administrative burden, Affordable Care Act.

The findings come from the multicenter SAVE-O2 AI trial, led by researchers at the University of Colorado Anschutz Medical Campus and published in JAMA Internal Medicine. The results were presented simultaneously at the Military Health System Research Symposium, highlighting the technology’s possible value not only in hospitals but also in military and emergency-care environments where clinical staff may be stretched thin.

The trial enrolled 300 adults at four U.S. hospitals, including UCHealth University of Colorado Hospital. Participants had acute respiratory illnesses, traumatic injuries, burns or conditions requiring surgical recovery, and all had recently begun receiving supplemental oxygen. They were randomly assigned either to conventional oxygen management, in which nurses or respiratory therapists adjusted flow rates, or to autonomous oxygen titration using the investigational O2matic PRO100 system.

Supplemental oxygen is usually delivered through devices such as nasal cannulas or face masks, with the flow rate adjusted according to intermittent measurements of a patient’s blood oxygen saturation. That saturation is estimated by pulse oximetry, a noninvasive technique that uses light to detect changes in the color of blood circulating through a fingertip sensor. Although pulse oximeters can provide continuous readings, standard hospital practice generally relies on clinicians checking the values periodically and manually changing oxygen delivery.

The automated system used the same basic physiological signal but responded to it continuously. When the patient’s oxygen saturation moved below the prescribed range, the device could increase oxygen flow; when the level rose too high, it could reduce delivery. This closed-loop approach is designed to compensate for the rapid fluctuations that can occur as patients breathe, move, sleep, receive medication or experience changes in their underlying illness. Instead of waiting for the next clinical assessment, the system adjusted oxygen in near real time.

Patients assigned to automated therapy spent 85 percent of the monitored period within their target oxygen range, a 22-percentage-point improvement over standard care. They also spent less time in hypoxemia, the condition in which blood oxygen levels fall too low, and less time in hyperoxemia, when oxygen levels exceed the intended range. The investigators further reported that clinical staff made fewer manual adjustments for patients in the automated group.

The distinction between too little and too much oxygen is clinically important. Insufficient oxygen can deprive organs such as the brain and heart of the oxygen they need to function. Excess oxygen, once widely assumed to be harmless, may also cause problems in some critically ill patients, including oxidative stress and injury to vulnerable tissues. For that reason, modern oxygen therapy increasingly emphasizes maintaining a patient-specific target range rather than simply delivering as much oxygen as possible.

“Oxygen is one of the most widely used therapies in medicine,” said Adit Ginde, the study’s principal investigator and a professor of emergency medicine at the University of Colorado Anschutz School of Medicine. Yet oxygen delivery remains largely dependent on repeated manual adjustments. According to Ginde, autonomous titration could help patients stay within their intended range more consistently while reducing both under-oxygenation and over-oxygenation.

David Douin, the study’s first author and an associate professor of anesthesiology at the University of Colorado Anschutz School of Medicine, said hospitalized patients’ oxygen requirements can change quickly. An automated system can react to those changes throughout the day and night, potentially reducing the periods during which a patient’s oxygen level drifts outside the target range. The trial found no increase in serious adverse events, an important safety result for a device that directly influences a core component of respiratory support.

The researchers caution that improved oxygen control does not by itself prove that the technology improves survival, shortens hospital stays or prevents long-term complications. The study primarily evaluated how much time patients spent within their prescribed oxygen range and how often staff needed to intervene. Future investigations will need to examine clinical outcomes, workload changes, performance in more severely ill patients and the system’s reliability during transport or in settings with limited monitoring resources.

The research has particular relevance to military medicine, where medics may care for wounded service members far from a hospital while simultaneously managing bleeding, airway problems and other life-threatening injuries. Vik Bebarta, chair of emergency medicine and founding director of the CU Anschutz Combat Medicine Research Center, said a device capable of adjusting oxygen independently could remove one recurring task from an overloaded medic’s responsibilities. The team is now planning additional evaluations in emergency transport and prehospital care.

The O2matic PRO100 was investigational in the United States and had not been cleared or approved by the Food and Drug Administration for commercial use. It was rented from O2matic of Denmark for research purposes, while the company had no role in study design, data collection, analysis or publication decisions. The trial was conducted under an FDA Investigational Device Exemption and was supported by the Defense Health Agency’s Combat Casualty Care Portfolio, the Medical Technology Enterprise Consortium and the National Center for Advancing Translational Sciences.

Subject of Research: Automated oxygen delivery and real-time oxygen titration for hospitalized patients.

Article Title: SAVE-O2 AI trial of autonomous oxygen titration in hospitalized adults.

Web References: JAMA Internal Medicine article; University of Colorado Anschutz; O2matic.

References: Ginde A, Douin D and colleagues, SAVE-O2 AI trial, JAMA Internal Medicine; CU Anschutz Combat Medicine Research Center.

Keywords: artificial intelligence, oxygen therapy, automated oxygen delivery, pulse oximetry, hypoxemia, hyperoxemia, hospital medicine, emergency medicine, military medicine, clinical trial.

One of the most urgent applications involves protecting people from wildfire smoke. As climate change contributes to more frequent and severe wildfires across the western United States, air pollution is becoming a recurring medical threat. Fine particulate matter, particularly particles smaller than 2.5 micrometers in diameter, can penetrate deep into the lungs and enter the bloodstream, worsening asthma, chronic obstructive pulmonary disease, cardiovascular conditions, and other illnesses. Researchers at the University of California, Davis, have developed a Population Health Wildfire Preparedness and Management Model that uses electronic health records, air-quality measurements, and patient ZIP codes to identify people most vulnerable to hazardous exposure.

The model is designed to turn environmental data into targeted preventive action. By linking clinical information with local pollution levels, it can determine which patients may face an elevated risk during a wildfire event and send them tailored instructions, such as staying indoors, using air filtration, limiting strenuous activity, or seeking medical assistance. The approach represents a shift from responding to smoke-related hospital visits to anticipating them before they occur. Future versions could incorporate artificial intelligence to improve risk prediction, extend coverage across California and other regions, and customize alert thresholds according to local climate conditions and individual medical histories.

Digital tools are also being deployed to address the United States’ persistent maternal health crisis, particularly in rural communities where hospitals and obstetric units are disappearing. Pregnant patients living far from specialist care may now use a combination of smartphone applications, connected medical devices, and home-based imaging systems to monitor their health between clinical visits. The Pregnancy+ app provides prenatal education and guidance for navigating health services, while Bluetooth-enabled blood-pressure cuffs transmit measurements for remote review. This is particularly important for detecting hypertension, a major warning sign of pre-eclampsia that can rapidly become life-threatening.

Another platform, Pulsenmore ES, is an FDA-cleared home-use prenatal ultrasound system intended to extend selected forms of fetal monitoring beyond the clinic. Such systems do not replace obstetricians or emergency care, but they can support surveillance when patients have limited transportation or live far from hospitals. Technically, the model depends on reliable data transmission, clear imaging protocols, clinical interpretation, and escalation pathways when measurements appear abnormal. Evidence from a 2025 review suggests that rural maternal programs are most effective when digital services complement, rather than substitute for, in-person care. The technology works best as part of a hybrid system combining remote monitoring with trained professionals and physical access to treatment.

The social consequences of digital health policy are explored in a report on Australia’s legislation restricting social-media access for children younger than 16. Supporters argue that age limits could reduce exposure to harmful content, cyberbullying, addictive platform design, and predatory behavior. Critics warn that broad bans may drive young users toward smaller, less regulated services where safety controls are weaker. The report notes estimates that as many as 85% of underage users remained on social media after the Australian restrictions, potentially by circumventing age-verification systems or moving to alternative platforms. Canada’s newly introduced Safe Social Media Act has intensified the debate over whether regulation can protect children without cutting them off from social connection, peer support, and reliable information.

The technical challenge is considerable because age assurance systems must distinguish minors from adults without creating new privacy hazards. Facial estimation, identity documents, behavioral analysis, and device-based verification all involve trade-offs between accuracy, surveillance, data retention, and exclusion. A system that blocks legitimate users may disproportionately affect young people who depend on online communities, including those who are isolated, disabled, or seeking support for sensitive health concerns. The debate illustrates why digital safety cannot be measured only by whether access is blocked. Effective policy must also account for evasion, platform migration, privacy protection, and the quality of the online environments that remain available.

China’s consumer health market offers a different vision of how artificial intelligence can be integrated into medicine. In an analysis of Ping An Good Doctor, JD Health, Alibaba Health, and WeDoctor, JMIR Correspondent Tejas S Athni describes these services not simply as chatbots or symptom checkers, but as AI-enabled health ecosystems. Their functions can connect telemedicine consultations with pharmacy services, hospital scheduling, medical information, and chronic-disease management. In practical terms, users may receive automated guidance, consult a clinician remotely, obtain medication, and arrange follow-up care within a connected digital environment.

This model has emerged partly in response to structural pressures in China’s health system, including a shortage of physicians relative to the population, substantial differences in hospital quality between urban and rural regions, and overcrowded outpatient departments. Machine-learning systems can help triage requests, organize patient information, identify patterns in longitudinal data, and direct people toward appropriate services. Yet these benefits depend on data quality, interoperability, clinical validation, and safeguards against algorithmic errors. An AI ecosystem that controls multiple stages of care may improve convenience while also concentrating sensitive health information and increasing the consequences of incorrect recommendations.

Artificial intelligence is entering operating rooms as well. Surgical systems are being developed for education, preoperative imaging, anatomical measurement, procedure planning, clinical decision support, and robotic assistance. Some systems can analyze imaging data to identify structures or calculate surgical parameters, while robotic platforms may provide highly precise movements under clinician control. Research into increasingly autonomous surgical processes raises the possibility of machines performing selected tasks with limited direct intervention. However, the complexity of surgery means that technical performance is only one part of the safety equation. Unexpected anatomy, bleeding, equipment failure, and rapidly changing conditions require judgment that may not be captured by training datasets.

The expansion of surgical AI therefore brings unresolved questions about informed consent, cybersecurity, patient privacy, and liability. Patients should understand when an algorithm or robotic system is involved in their care, what decisions remain under human control, and how failures will be investigated. Hospitals and manufacturers must establish standards for testing, monitoring, software updates, and reporting adverse events. As these five reports show, digital health is becoming viral not merely because new tools are powerful, but because they connect medical decisions to environmental sensors, household devices, online platforms, and national health systems. The next phase of innovation will depend on whether scientific progress is matched by transparent governance, equitable access, and accountability.

Subject of Research: People

News Publication Date: July 31, 2026

Web References: https://www.jmir.org/2026/1/e107243; https://www.jmir.org/2026/1/e107344; https://www.jmir.org/2026/1/e107251; https://www.jmir.org/2026/1/e107537; https://www.jmir.org/2026/1/e107619

References: Virginia Gewin, “As Wildfires Rise Across the West, New Tools Aim to Protect At-Risk Populations”; Anika Nayak, “Digital Health Technologies Are Bridging the Maternal Mortality Gap”; Simon Spichak, “How Social Media and Chatbot Bans Could Backfire”; Tejas S Athni, “China’s AI-Enabled Consumer Health Ecosystems”; Jenna Congdon, “AI in the OR: Ethics and the Evolving Role of Surgeons.”

Keywords

Artificial intelligence, digital health, public health, environmental health, wildfire smoke, maternal health, prenatal care, pregnancy complications, telemedicine, remote monitoring, social media regulation, child online safety, China health technology, consumer health platforms, surgical AI, robotic surgery, medical technology, health equity.

This novel approach hinges on the application of machine learning algorithms to decode the brain’s complex electrical activity. Similar to how a linguist learns a new language by identifying patterns and inferring meaning, the algorithm constructs a comprehensive “dictionary” of brain waveforms. By recognizing frequently occurring patterns in EEG data and interpreting them in context, the system unveils nuances that escape even the sharpest human observers. This technology promises to reveal the hidden electrical language of the brain, providing insights into neurological functions and dysfunctions.

The proof-of-concept exploration employed genetic mouse models harboring variations in the TSC1 gene, known to provoke epileptic conditions. Unlike traditional studies that require seizure occurrences during EEG monitoring, this investigation focused purely on “normal” brain activity, capturing data segments free from visible seizure episodes. The algorithm successfully identified subtle, strain-dependent EEG differences that correlated with the presence of the pathogenic gene mutation. This discerning capability demonstrated that neurological alterations manifest in baseline brain activity, even sans overt symptoms.

Notably, the research leveraged a diverse group of over 40 mice, encompassing three distinct genetic strains, which allowed the team to test the algorithm’s robustness across varied biological backgrounds. By analyzing EEG data collected over multiple days, the method demonstrated remarkable accuracy in differentiating seizure-prone mice from their healthy counterparts. These findings illuminate the possibility that epilepsy-related neural networks subtly alter brain rhythms, forming a detectable signature that could revolutionize diagnosis.

The University of Delaware collaborative effort stems from a synergistic partnership between the fields of computational neuroscience and biomedical engineering. Insights from Dr. Austin Brockmeier, an assistant professor specializing in electrical and computer engineering, melded with Dr. Amanda Hernan’s expertise in psychological and brain sciences, focusing on pediatric epilepsy. Their combined approach bridges computational rigor with clinical relevance, targeting tangible improvements in diagnostic precision and patient outcomes.

Looking forward, the research team is poised to translate these technical innovations from murine models to human clinical settings. Supported by funding from the Delaware Clinical and Translational Research ACCEL Program, ongoing studies aim to apply the AI algorithm to pediatric EEG recordings from children undergoing epilepsy evaluation at Nemours Children’s Health. Pediatric EEGs pose additional challenges due to their brevity and the heterogeneity of epilepsy manifestations, but the team remains hopeful that their refined analytical tools will uncover neural biomarkers predictive of disease onset.

A significant virtue of this AI-driven method lies in its capacity to detect brain activity changes long before seizures manifest, potentially enabling preemptive therapeutic interventions. By capturing subtle fluctuations in the brain’s electrical landscape, the system could provide neurologists with a real-time window into disease progression and treatment efficacy, circumventing the current trial-and-error approach. Such early detection would not only hasten diagnosis but also reduce the considerable psychological burden inflicted on families grappling with the uncertainty of epilepsy’s unpredictable cycles.

Beyond diagnosis, the research anticipates broader clinical impacts, including enhanced treatment management. Clinicians frequently face difficulties in assessing medication effectiveness because seizures naturally wax and wane over time. Advanced AI tools capable of continuous EEG pattern recognition could disentangle medication effects from natural seizure-free intervals, guiding data-driven decisions for optimized care.

Further horizons envision wearable EEG technologies integrated with AI analytics, permitting continuous monitoring of high-risk individuals in real-world environments. This real-time vigilance could transform patient care, offering timely alerts and personalized intervention windows. Moreover, analogous machine learning frameworks might be adapted for other complex neurological disorders, including autism spectrum disorders and attention deficit hyperactivity disorder (ADHD), underscoring the versatility and transformative potential of AI in neuroscience.

In essence, this research innovates at the nexus of neuroengineering and precision medicine. Brain-wave typing offers a novel frontier for understanding individualized neural signatures and tailoring interventions that align with each patient’s unique profile. The promise of such advances extends beyond technological novelty, holding the potential to improve lives by delivering clarity, reducing uncertainty, and ultimately guiding more effective treatments in epilepsy and beyond.

The journey from dissecting mouse brain waves to deploying AI-powered clinical diagnostics reflects a powerful example of translational neuroscience. University of Delaware’s interdisciplinary approach showcases how integrating computational algorithms with clinical neuroscience can pave the way for next-generation diagnostic tools. As the technology evolves, it will be critical to ensure robust validation, ethical data use, and seamless integration into healthcare settings to maximize benefit for patients.

Epilepsy’s characteristic unpredictability has long frustrated patients and physicians alike. By transforming the chaotic and complex electrical patterns of the brain into intelligible data, this AI approach offers hope for a future where epilepsy is diagnosed earlier, managed more effectively, and understood more deeply. The implications for reducing the emotional toll on patients and families could be profound, underscoring the vital role of technological innovation in human health.

Subject of Research: Animals

Article Title: Interpretable EEG biomarkers for neurological disease models in mice using bag-of-waves classifiers

News Publication Date: 20-May-2026

Web References:
https://iopscience.iop.org/article/10.1088/1741-2552/ae4d8c

References:
Journal of Neural Engineering, DOI: 10.1088/1741-2552/ae4d8c

Image Credits: Courtesy of The University of Delaware

Keywords: Neurological disorders, Seizures, Epilepsy, EEG, Artificial Intelligence, Machine Learning, Computational Neuroscience, Pediatric Epilepsy, Brain-wave Analysis, Precision Medicine, Biomarkers